Analysts Set Nektar Therapeutics (NASDAQ:NKTR) PT at $1.50

Shares of Nektar Therapeutics (NASDAQ:NKTR) have earned a consensus rating of “Hold” from the five brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $1.50.

Separately, Rodman & Renshaw assumed coverage on Nektar Therapeutics in a report on Friday, June 28th. They issued a “buy” rating and a $2.00 price target on the stock.

Nektar Therapeutics Stock Up 4.8 %

NASDAQ:NKTR opened at $1.31 on Wednesday. The business’s 50 day moving average is $1.28 and its two-hundred day moving average is $1.27. Nektar Therapeutics has a 52 week low of $0.41 and a 52 week high of $1.93. The company has a market cap of $241.14 million, a PE ratio of -1.42 and a beta of 0.60.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Nektar Therapeutics had a negative return on equity of 133.64% and a negative net margin of 190.09%. The firm had revenue of $23.49 million for the quarter, compared to the consensus estimate of $17.24 million. During the same period in the prior year, the business earned ($0.27) EPS. As a group, sell-side analysts expect that Nektar Therapeutics will post -0.85 EPS for the current fiscal year.

Institutional Trading of Nektar Therapeutics

Hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. bought a new stake in shares of Nektar Therapeutics in the 2nd quarter worth approximately $29,000. Values First Advisors Inc. bought a new stake in Nektar Therapeutics during the 2nd quarter valued at $56,000. State Board of Administration of Florida Retirement System bought a new stake in Nektar Therapeutics during the 1st quarter valued at $63,000. SG Americas Securities LLC raised its stake in Nektar Therapeutics by 63.0% during the 2nd quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock valued at $91,000 after acquiring an additional 28,338 shares in the last quarter. Finally, Candriam S.C.A. bought a new stake in Nektar Therapeutics during the 2nd quarter valued at $99,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.